Amgen is awaiting another Phase 3 readout for the investigational Sjögren’s disease therapy, set for later this year. William Blair anticipates that at least two trials will be needed to support an FDA application.
Amgen asset from $27.8B Horizon buy scores in Phase 3 Sjögren’s study